At this week’s 2022 H.C. Wainwright BioConnect Virtual Conference, NRx identified the plans to move forward with a vanguard trial of the BriLife investigational vaccine for COVID-19 as a heterologous booster for those already vaccinated with mRNA vaccines.
NRX
Jan. 14, 2022
CEO Update: BriLife Investigational Vaccine for COVID-19 as a Booster
Jan. 12, 2022
NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics
NRx Pharmaceuticals (Nasdaq: NRXP) filed a lawsuit on Monday against Relief Therapeutics (SIX: RLF,OTCQB: RLFTF, RLFTY), its former collaboration partner, in New York State Supreme Court.
Dec. 15, 2021
NRx Pharmaceuticals Added to the Nasdaq® Biotech Index
NRx Pharmaceuticals announced that Nasdaq has added the company to the Nasdaq Biotechnology Index (Nasdaq:NBI) effective December 20, 2021. The NBI is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.